利生奇珠单抗治疗中重度斑块状银屑病伴非脓疱性掌跖受累的3b期随机研究
该3b期随机研究评估利生奇珠单抗(RZB)对比安慰剂(PBO)治疗伴非脓疱性掌跖受累的中重度斑块状银屑病成人患者的安全性与疗效。第16周时RZB在ppIGA 0/1、PPASI 75/90/100及sPGA 0/1等终点均显著优于PBO,疗效持续至第52周且无新安全信号。
要点
- 疗效持续改善至第52周,未见新安全信号。
核心结论
- RZB在掌跖银屑病中显示出良好的耐受性和疗效。
研究设计与样本
- 随机、安慰剂对照的3b期研究,患者随机接受RZB或PBO治疗16周,随后RZB治疗至第52周。
关键数值与推荐
- 主要和次要终点为第16周达到ppIGA 0/1、PPASI 75/90/100及sPGA 0/1。
- 安全性基于治疗中出现的不良事件评估。
临床怎么用
- 对于伴非脓疱性掌跖受累的中重度斑块状银屑病成人患者,RZB可作为治疗选择之一。
局限性
- 研究未设生物制剂对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In plaque psoriasis, palmoplantar areas are more difficult to treat. OBJECTIVE: Evaluate the safety and efficacy of risankizumab (RZB) versus placebo (PBO) for the treatment of palmoplantar psoriasis. METHODS: Patients were randomized to RZB or PBO for 16 weeks followed by RZB through week 52. The primary and secondary end points were achievement of palmoplantar Investigator's Global Assessment of "clear" or "almost clear" with ≥2-point reduction from baseline (ppIGA 0/1), achievement of ≥75%, ≥90%, and 100% improvement in Palmoplantar Psoriasis Area and Severity Index (PPASI 75, PPASI 90, PPASI 100) and achievement of static Physician Global Assessment of "clear" or "almost clear" with ≥2-point reduction from baseline (sPGA 0/1) at week 16. Safety was based on treatment-emergent adverse events. RESULTS: RZB demonstrated significant efficacy compared to PBO at week 16 in the patients achieving ppIGA 0/1 (33.3% vs 16.1% [P = .006]), PPASI 75 (42.5% vs 14.9% [P < .001]), PPASI 90 (27.6% vs 5.7% [P < .001]), sPGA 0/1 (32.2% vs 11.5% [P < .001]), and PPASI 100 (17.2% vs 1.1% [P < .001]). Results improved through week 52 with no new safety signals. LIMITATION: No biologic comparator. CONCLUSIONS: RZB demonstrated good tolerance and efficacy in palmoplantar psoriasis.
引用
- Lebwohl M, Bukhalo M, Stein Gold L, et al. A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement. J Am Acad Dermatol. 2024. PMID: 39208985. doi:10.1016/j.jaad.2024.07.1521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。